CARB-X supports BioVersys in the fight against antimicrobial resistance with up to almost 9 million dollars
BioVersys receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies:
Strekin AG Announces Completion of Patient Recruitment in th...
Congratulations to our tenants Polyneuron Pharmaceuticals, C...
Strekin AG Secures Financing to Complete Development of STR0...
Interview with Alex Mayweg, partner at Versant Ventures and ...
Swiss Technology Award 2019